▴ Lacosamide is a functionalized amino acid, the antiepileptic effects of which appear to be due to a novel mode of action, namely the selective enhancement of slow inactivation of voltage-gated sodium channels.
▴ Lacosamide is available as oral or intravenous formulations. Bioequivalence between the oral tablet and the oral syrup of lacosamide has been established. The bioavailability of the oral lacosamide tablet was similar to that of a 30- or 60-minute intravenous infusion of lacosamide administered at the same dosage.
▴ Oral lacosamide when added concomitantly with between one and three antiepileptic drugs was effective in adult patients with uncontrolled partialonset seizures with or without secondary generalization, according to pooled data (n= 1308) from three phase II/III studies that had a 12-week maintenance phase. The percentage of patients with a ≥50% reduction from baseline to the maintenance phase in seizure frequency was significantly greater with oral lacosamide 200 or 400 mg/day (34% and 40%) than with placebo (23%).
▴ The median percentage reduction in seizure frequency per 28 days from baseline to the maintenance phase was significantly greater with lacosamide 400 mg/day than with placebo in each of the three phase II/III studies.
▴ Lacosamide was generally well tolerated in adult patients with partial-onset seizures, with most treatment-emergent adverse events being of mild or moderate severity. Dizziness was the most common treatment-related adverse event. When used as short-term replacement for oral lacosamide, intravenous lacosamide was well tolerated when administered as a 15-, 30- or 60-minute infusion.
KeywordsSeizure Frequency Lacosamide Median Percentage Reduction Adis Drug Profile Oral Lacosamide
Unable to display preview. Download preview PDF.
- 1.UK National Institute for Clinical Excellence. Technology appraisal guidance 76: newer drugs for epilepsy in adults [online]. Available from URL: http://www.nice.org.uk/Guidance/TA76 [Accessed 2007 Feb 27]
- 6.European Medicines Agency. Lacosamide (Vimpat®): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/vimpat/H-863-PI-en.pdf [Accessed 2008 Nov 5]
- 9.US FDA. Vimpat® (lacosamide) tablets and injection: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/022253lbl.pdf [Accessed 2008 Oct 30]
- 16.Biomedical systems. Thorough QT trials [online]. Available from URL: http://www.biomedsys.com/Docs/Thorough%20QT%20Trials%201-15-07.pdf [Accessed 2009 Mar 13]
- 17.Horstmann R, Zisowsky J, Thomas D. Lacosamide demonstrates no potential for QTc-prolongation [abstract no. p245]. Epilepsia 2007 Oct; 48 Suppl. 7: 107Google Scholar
- 18.European Medicines Agency. Assessment report for Vimpat (lacosamide) [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/vimpat/H-863-en6.pdf [Accessed 2008 Oct 3]
- 20.Cawello W, Kropeit D, Schiltmeyer B, et al. Food does not affect the pharmacokinetics of SPM 927 [abstract no. 2.342]. Epilepsia 2004; 45 Suppl. 7: 307Google Scholar
- 21.Horstmann R, Bonn R, Cawello W, et al. Basic clinical pharmacologic investigations of the new antiepileptic drug SPM 927 [abstract no. 2.174]. Epilepsia 2002; 43 Suppl. 7: 188Google Scholar
- 24.Schiltmeyer B, Cawello W, Kropeit D, et al. Pharmacokinetics of the new antiepileptic drug SPM 927 in human subjects with different age and gender [abstract no. 2.361]. Epilepsia 2004; 45 Suppl. 7: 313Google Scholar
- 25.Hortsmann R, Bonn R, Cawello W, et al. SPM 927 does not interact with valproic acid and carbamazepine [abstract no. 1.271]. Epilepsia 2003; 44 Suppl. 9: 97Google Scholar
- 26.Schiltmeyer B, Thomas D, Horstmann R, et al. Lacosamide has no potential for interaction with metformin [abstract no. P869]. Diabet Med 2006 Dec 1; 23 Suppl. 4: 315–6Google Scholar
- 27.Thomas D, Scharfenecker U, Schiltmeyer B, et al. Low potential for drug-drug interaction of lacosamide [abstract no. 2.235]. Epilepsia 2006; 47 Suppl. 4: 200Google Scholar
- 28.Haläsz P, Kälviäinen R, Mazurkiewicz-Beldzinska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. Epub 2009 Jan 17Google Scholar
- 29.Chung S, Sperling M, Biton V, et al. Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures [abstract P02.097]. 60th Annual Meeting of the American Academy of Neurology; 2008 Apr 12–19, Chicago (IL)Google Scholar
- 30.International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy 1981; 22(4): 489–501Google Scholar
- 31.US National Institutes of Health. Assess safety and efficacy of lacosamide in patients with partial seizures (SP774) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Oct 8]
- 32.US National Institutes of Health. Determine safety and efficacy of long-term oral lacosamide in patients with partial seizures (SP756) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Oct 8]
- 33.US National Institutes of Health. To determine tolerability and efficacy of long-term oral lacosamide in patients with partial seizures (SP615) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Oct 3]
- 34.Rosenfeld W, Fountain NB, Kaubrys G, et al. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures [abstract no. 3.191]. Epilepsia 2007; 48 Suppl. 6: 318–9Google Scholar
- 35.Biton V, Fountain N, Rosenow F, et al. Safety and tolerability of lacosamide: summary of adverse events [abstract and poster]. Eight European Congress on Epileptology; 2008 Sep 21–25; BerlinGoogle Scholar
- 36.Krauss G, Ben-Menachem E, Mameniskiene R, et al. Safety, tolerability, and pharmacokinetic parameters of 10-, 15- and 30-minute intravenous infusions as short-term replacement therapy in subjects with partial onset seizures [abstract no. S45.008]. 60th Annual Meeting of the American Academy of Neurology; 2008 Apr 12–19; Chicago (IL)Google Scholar